An 8-week course of the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C in people with compensated cirrhosis, across a wide range of genotypes, Robert S. Brown of Weill Cornell Medical College reported at the AASLD Liver Meeting in San Francisco this week. Maviret is a highly effective combination of an HCV protease inhibitor (glecaprevir) and an NS5A inhibitor (pibrentasvir) that has been shown to cure hepatitis C in 98% of people without cirrhosis after eight weeks of treatment. A previous study showed that a 12-week course of the combination cured hepatitis C in 99% of people with compensated cirrhosis. The EXPEDITION-8 study was designed to test whether an 8-week treatment course was as effective in previously untreated people with compensated cirrhosis as the rate of cure achieved in the previous 12-week study.
Read more: http://www.infohep.org/page/3366911/
Meeting Coverage @ infohep Twitter - @infohep
HCV Combo Pill a Winner in Untreated Cirrhotic Patients
HCV Combo Pill a Winner in Untreated Cirrhotic Patients
High SVR12 rate suggests 8-week treatment could be used for this population
Read more: https://www.medpagetoday.com/meetingcoverage/aasld/76333
Coverage @ MedPage Today Twitter @medpagetoday
Recommended Coverage
Read more: https://www.medpagetoday.com/meetingcoverage/aasld/76333
Coverage @ MedPage Today Twitter @medpagetoday
Recommended Coverage
Presented at the AASLD: The Liver Meeting®
Preliminary efficacy & safety of 8-week GLE/PIB in patients with #HCV genotype 1-6 infection & compensated cirrhosis: The EXPEDITION-8 Study LINK
Download Slides: https://jumpshare.com/v/hfK0UhdJXgTFvWEY97tB
Shared via @HenryEChang on twitter.
No comments:
Post a Comment